Solu-Medrol

Solu-Medrol

methylprednisolone

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Methylprednisolone Na succinate
Indications/Uses
Adjunctive therapy for short-term management of acute episode or exacerbation post-traumatic OA, synovitis or OA, RA eg, juvenile RA, acute & subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute gouty & psoriatic arthritis, ankylosing spondylitis. Exacerbation or maintenance therapy of SLE, acute rheumatic carditis, systemic dermatomyositis, polyarteritis nodosa, Goodpasture's syndrome. Dermatologic, ophth, GI, resp & oncological diseases; allergic, edematous & shock states; hematologic, endocrine & nervous system disorders. Organ transplantation. TB meningitis, trichinosis, prevention of chemotherapy-induced nausea & vomiting.
Dosage/Direction for Use
Adjunct therapy in life-threatening conditions 30 mg/kg IV over at least 30 min, may be repeated every 4-6 hr up to 48 hr. Rheumatic disorders 1 g daily for 1-4 days or 1 g mthly for 6 mth as IV pulse over at least 30 min. Unresponsive SLE treatment 1 g daily for 3 days as IV pulse over at least 30 min. Unresponsive multiple sclerosis treatment 500 mg or 1 g daily for 3 or 5 days as IV pulse over at least 30 min. Edematotous states 30 mg/kg every other day for 4 days or 1 g daily for 3, 5 or 7 days as IV pulse over at least 30 min. Prevention of chemotherapy-associated nausea & vomiting 250 mg IV over at least 5 min 1 hr prior to, during & after chemotherapy; may be given w/ metoclopramide/butyrophenone for severely emetogenic chemotherapy. Acute spinal cord injury 30 mg/kg as IV bolus over 15-min followed by 45-min pause & continuous IV infusion of 5.4 mg/kg/hr for 23 hr (w/in 3 hr of injury) & 47 hr (w/in 3-8 hr of injury). Adjunctive therapy in other indications Initially 10-500 mg IV depending on clinical condition. Subsequent doses may be administered IV or IM at intervals according to patient's condition & response. Childn & infant Not <0.5 mg/kg every 24 hr.
Contraindications
Hypersenstivity. Systemic fungal infection. Intrathecal & epidural route. Live or live, attenuated vaccines.
Special Precautions
Discontinue use in Kaposi's sarcoma patients. Not for traumatic brain injury. Not recommended in septic shock. Increased susceptibility to infection; active or latent TB; unusual stress, hypothalamic-pituitary adrenal axis suppression, Cushing's syndrome, hypothyroidism; DM; psychiatric effects; seizures, myasthenia gravis; ocular herpes simplex, posterior subcapsular & nuclear cataracts (particularly in childn), exophthalmos or increased IOP, central serous chorioretinopathy; existing CV risk factors, CHF; thromboembolic disorders, HTN; acute pancreatitis, non-specific ulcerative colitis; osteoporosis; systemic sclerosis; BP elevation; pheochromocytoma crisis. Dietary salt restriction & K supplementation. Avoid abrupt w/drawal. Long-term & high-dose use. Not to be used w/ live or live, attenuated vaccine. Concomitant use w/ aspirin & NSAIDs; neuromuscular-blocking drugs eg, pancuronium. May affect ability to drive & use machines. Renal insufficiency. Hepatobiliary effects. Impairment of fertility. Pregnancy & lactation. Infants, growth suppression in childn.
Adverse Reactions
Arachnoiditis, functional GI disorder/bladder dysfunction, headache, meningitis, paraparesis/paraplegia, seizure, sensory disturbances.
Drug Interactions
Altered metabolism by induction (up-regulation) or inhibition of CYP3A4 enzyme. Decreased hepatic clearance by CYP3A4 inhibitor. Increased hepatic clearance by CYP3A4 inducers. Increased risk of systemic side effects w/ cobicistat-containing products. Increased acetylation rate & clearance of INH. Diminished & enhanced effects of oral anticoagulants. Antagonism of neuromuscular blocking effects of pancuronium, vecuronium. Reduced effects of anticholinesterases. Increase blood glucose conc w/ antidiabetics. Increased plasma conc by PIs eg, indinavir, ritonavir. Induced HIV-PIs metabolism. Exacerbated endocrine changes w/ aminoglutethimide. Convulsions w/ cyclosporine. Increased GI bleeding & ulceration w/ NSAIDs. Increased high-dose aspirin clearance. Increased risk of hypoglycemia w/ K-depleting agents eg, diuretics, amphotericin B, xanthines or β2-agonists. Incompatibility w/ allopurinol Na, doxapram HCl, tigecycline, diltiazem HCl, Ca gluconate, vecuronium Br, rocuronium Br, cisatracurium besylate, glycopyrrolate, propofol.
MIMS Class
Corticosteroid Hormones
ATC Classification
H02AB04 - methylprednisolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
Presentation/Packing
Form
Solu-Medrol powd for inj 1,000 mg
Packing/Price
1's
Form
Solu-Medrol powd for inj 500 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in